Sandoz and Pear Therapeutics have announced that Pear will now market alone the reSET and reSET-O digital therapeutics for treating substance use disorder and opioid use disorder that the pair launched in the US almost a year ago.
Sandoz Breaks Off Digital Deal With Pear
Decision Follows Change In Sandoz Leadership
Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.
More from Strategy
More from Business
• By
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.
• By
With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.
• By
Denosumab competition is heating up in Europe, with four more companies this month gaining EMA endorsements for their Prolia and Xgeva biosimilar rivals.